Last Updated: May 30, 2026

Details for New Drug Application (NDA): 020677


✉ Email this page to a colleague

« Back to Dashboard


NDA 020677 describes ZAGAM, which is a drug marketed by Mylan and is included in one NDA. Additional details are available on the ZAGAM profile page.

The generic ingredient in ZAGAM is sparfloxacin. Additional details are available on the sparfloxacin profile page.
Summary for 020677
Tradename:ZAGAM
Applicant:Mylan
Ingredient:sparfloxacin
Patents:0

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength200MG
Approval Date:Dec 19, 1996TE:RLD:No

Expired US Patents for NDA 020677

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan ZAGAM sparfloxacin TABLET;ORAL 020677-001 Dec 19, 1996 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.